Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Limitations with CAR T-cell therapy in CLL and lymphoma

Tanya Siddiqi • 26 Mar 2019
EBMT 2019
General CAR-T JCAR017
TRANSCEND-CLL-004

Tanya Siddiqi, MD, from the City of Hope National Medical Center, Duarte, CA, addresses the challenges with CAR T-cell therapy. Dr Siddiqi was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Tanya Siddiqi

0:59
The potential of combination therapies to improve CAR-T outcomes in patients with CLL
Tanya Siddiqi • 10 Dec 2023
0:54
A research update in Richter's transformation from ASH 2023
Tanya Siddiqi • 10 Dec 2023
3:12
Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004
Tanya Siddiqi • 10 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals